Drugs / SYS6020
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06359509 | Apr 2024 → May 2027 expected | plasma cell myeloma | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT06688435 | Jan 2025 → Dec 2028 expected | myasthenia gravis | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06694298 | Dec 2024 → Jan 2029 expected | systemic lupus erythematosus | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2024-10-25 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - FIRST mRNA-LNP-BASED CAR-T CELL INJECTION (SYS6020) OBTAINS FURTHER CLINICAL TRIAL APPROVAL FOR NEW INDICATION irasia.com ↗
The board of directors (the ‘‘Board ’’) of CSPC Pharmaceutical Group Limited (the ‘‘Company ’’, together with its subsidiaries, the ‘‘Group ’’) is pleased to announce that the first mRNA-Lipid Nanoparticles (LNP)-based Chimeric Anti gen Receptor (CAR)-T Cell Injection (SYS6020) (the ‘‘Product ’’) developed by the Group has obtained approval from the National Medical Products Administration of the People ’s Republic of China to conduct clinical trials for the indication of myasthenia gravis (MG ) in China. |
| 2024-08-09 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - FIRST mRNA-LNP-BASED CAR-T CELL INJECTION (SYS6020)OBTAINS CLINICAL TRIAL APPROVAL FOR NEW INDICATION irasia.com ↗
The board of directors (the ‘‘Board ’’) of CSPC Pharmaceutical Group Limited (the ‘‘Company ’’, together with its subsidiaries, the ‘‘Group ’’) is pleased to announce that the first mRNA-Lipid Nanoparticles (LNP)-based Chimeric Anti gen Receptor (CAR)-T Cell Injection (SYS6020) targeting B-cell maturation antigen ( BCMA) (the ‘‘Product ’’) developed by the Group has obtained approval from the Nation al Medical Products Administration of the People ’s Republic of China to conduct clinical trials for the indica tion of systemic lupus erythematosus (SLE) in China. |
| 2024-06-25 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - FIRST mRNA-LNP-BASED CAR-T CELL INJECTION (SYS6020) OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-10-25 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - FIRST mRNA-LNP-BASED CAR-T CELL INJECTION (SYS6020) OBTAINS FURTHER CLINICAL TRIAL APPROVAL FOR NEW INDICATION irasia.com ↗ |
| 2024-08-09 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - FIRST mRNA-LNP-BASED CAR-T CELL INJECTION (SYS6020)OBTAINS CLINICAL TRIAL APPROVAL FOR NEW INDICATION irasia.com ↗ |
| 2024-06-25 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - FIRST mRNA-LNP-BASED CAR-T CELL INJECTION (SYS6020) OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYS6020 | “A Phase І Study of BCMA-targeted Chimeric Antigen Receptor T Cell (SYS6020) Injection in Relapsed or Refractory Multiple Myeloma” NCT06359509 ↗ |
| Modality | Cell therapy | “BCMA-targeted Chimeric Antigen Receptor T Cell (SYS6020) Injection” NCT06359509 ↗ |
| Route | Intravenous | “Each patient will receive BCMA Targeted CAR T-cells by intravenous infusion.” NCT06359509 ↗ |